1.25
+0.01(+0.81%)
Currency In USD
| Previous Close | 1.24 |
| Open | 1.23 |
| Day High | 1.25 |
| Day Low | 1.22 |
| 52-Week High | 3.09 |
| 52-Week Low | 0.26 |
| Volume | 631,707 |
| Average Volume | 1.01M |
| Market Cap | 230.55M |
| PE | -5.68 |
| EPS | -0.22 |
| Moving Average 50 Days | 1.16 |
| Moving Average 200 Days | 1.2 |
| Change | 0.01 |
If you invested $1000 in Tevogen Bio Holdings Inc. (TVGN) since IPO date, it would be worth $125.75 as of July 01, 2025 at a share price of $1.25. Whereas If you bought $1000 worth of Tevogen Bio Holdings Inc. (TVGN) shares 2 years ago, it would be worth $117.15 as of July 01, 2025 at a share price of $1.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
GlobeNewswire Inc.
10 hours ago
Contribution highlights leadership’s understanding of the importance AI will play in drug discovery WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that founder and C
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
GlobeNewswire Inc.
Jun 18, 2025 12:30 PM GMT
WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-assoc
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
GlobeNewswire Inc.
Jun 09, 2025 1:00 PM GMT
R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency.Tevogen.AI, strengthened by its partnership with Microsoft, continues to expand. An update on AI and other Company assets